Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Trial Profile

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Saposin C (Primary)
  • Indications Glioblastoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bexion Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2016 According to a Bexion Pharmaceuticals media release, first patient has been dosed in this trial, at the University of Cincinnati Cancer Institute.
    • 12 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 18 Jul 2016 According to Bexion Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) cleared Bexion's application to initiate this First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top